← Leaderboards
Reina Haque
Kaiser Foundation Research Institute
$5,883,468
Attributed
$9,922,179
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2010–25$2.5M$1.9M$1.3M$625K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,922,179 · 5
By mechanism
R01$6,418,778 · 3
U01$3,343,401 · 1
R03$160,000 · 1
Top collaborators
- Arnold L Potosky7 shared
- Michael R Irwin5 shared
Most similar at Kaiser Foundation Research Institute
Same institution · by research overlap
- Lawrence H Kushi$60,993,337
- Barbara Sternfeld$4,196,318
- Marilyn L Kwan$12,106,221
- Song Yao$11,329,919
- Bette J Caan$23,657,335
Others in their field
Top investigators on “California”
- Gary D Acton · University Of California-Davis$320,373,312
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Judith S. Currier · University Of California Los Angeles$152,313,768
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$137,892,773
- Sharon A Nachman · Johns Hopkins University$135,132,510
Research focus
CaliforniaMalignant NeoplasmsMemberMalignant Breast NeoplasmCharacteristicsDiagnosisCohortWomanFollow-UpRecording Of Previous EventsCancer TherapyMental DepressionReportingAdjuvantComorbidityEvidence BaseAgingRisk FactorsMortalityPublic HealthMorbidity - Disease RateBreast Cancer SurvivorBaseAffect
Grant awards (17)
Longitudinal assessment of benefits and harms of cannabis use among community-based cancer patients during initial cancer treatment$2,015,377
U01 · FY2025 · CA
Longitudinal assessment of benefits and harms of cannabis use among community-based cancer patients during initial cancer treatment$627,896
U01 · FY2024 · CA
Longitudinal assessment of benefits and harms of cannabis use among community-based cancer patients during initial cancer treatment$700,128
U01 · FY2023 · CA
Risk prediction of breast cancer treatment-related cardiotoxicity to guide clinical decision making$368,787
R01 · FY2023 · HL · contact PI
Risk prediction of breast cancer treatment-related cardiotoxicity to guide clinical decision making$375,049
R01 · FY2022 · HL · contact PI
Risk prediction of breast cancer treatment-related cardiotoxicity to guide clinical decision making$378,169
R01 · FY2021 · HL · contact PI
Sleep Disturbance, Inflammation, and Cellular Aging in Breast Cancer Survivors$623,679
R01 · FY2020 · CA
Risk prediction of breast cancer treatment-related cardiotoxicity to guide clinical decision making$411,468
R01 · FY2020 · HL · contact PI
Sleep Disturbance, Inflammation, and Cellular Aging in Breast Cancer Survivors$616,550
R01 · FY2019 · CA
Is depression associated with prostate cancer progression?$80,000
R03 · FY2019 · CA · contact PI
Sleep Disturbance, Inflammation, and Cellular Aging in Breast Cancer Survivors$643,101
R01 · FY2018 · CA
Is depression associated with prostate cancer progression?$80,000
R03 · FY2018 · CA · contact PI
Sleep Disturbance, Inflammation, and Cellular Aging in Breast Cancer Survivors$650,220
R01 · FY2017 · CA
Sleep Disturbance, Inflammation, and Cellular Aging in Breast Cancer Survivors$666,998
R01 · FY2016 · CA
ABC: Antidepressants and Breast Cancer Pharmacoepidemiology$490,004
R01 · FY2012 · CA · contact PI
ABC: Antidepressants and Breast Cancer Pharmacoepidemiology$560,483
R01 · FY2011 · CA · contact PI
ABC: Antidepressants and Breast Cancer Pharmacoepidemiology$634,270
R01 · FY2010 · CA · contact PI